LONDON, Nov. 2, 2017 /PRNewswire/ -- Hospital-acquired infection Diagnostics Market by Product (Instrument and Reagents and Consumables) by Test Type (Molecular Diagnostics, Urinalysis, and Immunoassay) by Application (Disease Testing and Drug-Resistance Testing), by Infection Type (Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, Urinary Tract Infections (UTI), and Others) and by End User (Hospital, Clinics, Ambulatory Surgery Centres (ASC) and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Download the full report: https://www.reportbuyer.com/product/5139398

Hospital-acquired infections are type of infections acquired during hospitalization and are commonly known as nosocomial infection. These infections can be acquired in hospital, nursing home, rehabilitation facility, outpatient clinic, or other clinical settings. They can be acquired from an infected patient, outside environment, or from a staff of that facility. The hospital-acquired infection diagnostics market is primarily driven by the growth in awareness among healthcare workers and proposed government initiatives by many governmental organizations. Further, in developing economies such as China, India, and Brazil, the cleanliness and hygiene is minimum. Hence, it results in more hospital-acquired infections, which further increases the demand for hospital-acquired infection diagnostics. However, the decline in hospital-acquired infections in the developed countries such as the U.S., Germany, and the UK impedes the market growth. The hospital-acquired infection diagnostics market was valued at $2,571 million in 2016, and is expected to reach at $4,311 million by 2023, registering a CAGR of 7.5% from 2017 to 2023.

The hospital-acquired infection diagnostics market is segmented based on product, test type, application, infection type, end user and region. Based on product this market is segmented into instrument and reagents and consumables. Based on test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. Based on application, the market is divided into disease testing and drug resistance testing. Further, based on infection type, it is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal Infections, urinary tract infections (UTI), and others. Based on end user this market is segmented into hospital, clinics, ambulatory surgery centres (ASC) and others. By region, the market is analysed across North America, Europe, Asia-Pacific, and LAMEA.

Infection Control Homepage